PTGS2 and breast carcinoma: Celecoxib (CXB), a selective COX-2 inhibitor, can effectively prevent the development of chemoresistance in breast cancer cells induced by doxorubicin (DOX) by suppressing P-gp expression and function, and furthermore synergistically boost the cytotoxicity of DOX in these drug-resistant cells [15–18].